Neurofibromatosis type 1: a multidisciplinary approach to care (Q38230259)

31 August 2017

title

Neurofibromatosis type 1: a multidisciplinary approach to care (English)

1 reference

31 August 2017

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25030515 AND SRC:MED&resulttype=core&format=json

12 June 2020

author name string

Angela C Hirbe

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25030515 AND SRC:MED&resulttype=core&format=json

12 June 2020

publication date

1 August 2014

1 reference

31 August 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25030515 AND SRC:MED&resulttype=core&format=json

12 June 2020

volume

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25030515 AND SRC:MED&resulttype=core&format=json

12 June 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25030515 AND SRC:MED&resulttype=core&format=json

12 June 2020

page(s)

834-843

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25030515 AND SRC:MED&resulttype=core&format=json

Prevalence of Neurofibromatosis 1 in German Children at Elementary School Enrollment

12 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

Von Recklinghausen neurofibromatosis. A clinical and population study in south-east Wales

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

Neurofibromatosis type 1 revisited

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

Mechanisms in the pathogenesis of malignant tumours in neurofibromatosis type 1.

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

Rethinking pediatric gliomas as developmental brain abnormalities.

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

Duodenal carcinoids in patients with and without neurofibromatosis. A comparative study

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

Increased risk of breast cancer in women with NF1.

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

Mortality in neurofibromatosis 1: an analysis using U.S. death certificates.

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

Second primary tumors in neurofibromatosis 1 patients treated for optic glioma: substantial risks after radiotherapy.

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

Neurofibromatosis in children with Rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma study IV.

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

Breast cancer and other neoplasms in women with neurofibromatosis type 1: a retrospective review of cases in the Detroit metropolitan area

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

Neurofibromatosis type 1: modeling CNS dysfunction

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

Why do benign astrocytomas become malignant in NF1?

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

Somatic neurofibromatosis type 1 (NF1) inactivation characterizes NF1-associated pilocytic astrocytoma

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

Deletions spanning the neurofibromatosis type 1 gene: implications for genotype-phenotype correlations in neurofibromatosis type 1?

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

Familial neurofibromatosis 1 microdeletions: Cosegregation with distinct facial phenotype and early onset of cutaneous neurofibromata

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

Elevated risk for MPNST in NF1 microdeletion patients

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

Guidelines for the diagnosis and management of individuals with neurofibromatosis 1

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

Neurofibromatosis 1: clinical manifestations and diagnostic criteria

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

Tumorigenic properties of neurofibromin-deficient Schwann cells in culture and as syngrafts in Nf1 knockout mice.

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

Genetic and cellular defects contributing to benign tumor formation in neurofibromatosis type 1

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

Tumor microenvironment and neurofibromatosis type I: connecting the GAPs

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

Neurofibroma-associated growth factors activate a distinct signaling network to alter the function of neurofibromin-deficient endothelial cells

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

Nf1-dependent tumors require a microenvironment containing Nf1 /-- and c-kit-dependent bone marrow

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

Plexiform Neurofibromas in Children with Neurofibromatosis Type 1: Frequency and Associated Clinical Deficits

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

Phase I trial of pegylated interferon-alpha-2b in young patients with plexiform neurofibromas

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial.

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

Bone health and fracture rate in individuals with neurofibromatosis 1 (NF1).

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

A controlled register-based study of 460 neurofibromatosis 1 patients: increased fracture risk in children and adults over 41 years of age.

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

Generalized metabolic bone disease in Neurofibromatosis type I

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

Follow-up of six patients with neurofibromatosis 1-related osteoporosis treated with alendronate for 23 months

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

Bone mineral metabolism in patients with neurofibromatosis type 1 (von Recklingausen disease).

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

Bone mineral density in children and adolescents with neurofibromatosis type 1.

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

Effect of vitamin D3 treatment on bone density in neurofibromatosis 1 patients: A retrospective clinical study

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

Prevalence of scoliosis in neurofibromatosis

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

VEPTR™ Growing Rods for Early-onset Neuromuscular Scoliosis: Feasible and Effective

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

Calvarial defects and skeletal dysplasia in patients with neurofibromatosis Type 1.

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

Associations of osseous abnormalities in Neurofibromatosis 1.

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

The heart in neurofibromatosis type 1: an echocardiographic study

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

Cardiovascular malformations and other cardiovascular abnormalities in neurofibromatosis 1

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

Cardiovascular disease in neurofibromatosis 1: report of the NF1 Cardiovascular Task Force

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

Vascular abnormalities in patients with neurofibromatosis syndrome type I: clinical spectrum, management, and results

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

Neurofibromin-deficient myeloid cells are critical mediators of aneurysm formation in vivo

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

Loss of NF1 expression in human endothelial cells promotes autonomous proliferation and altered vascular morphogenesis

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

Cerebrovascular abnormalities in a population of children with neurofibromatosis type 1.

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

Cerebral arteriopathy in children with neurofibromatosis type 1.

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

The nature and frequency of cognitive deficits in children with neurofibromatosis type 1.

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

Neurofibromatosis type 1: new insights into neurocognitive issues

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

Lovastatin as treatment for neurocognitive deficits in neurofibromatosis type 1: phase I study

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

Gliomas in patients with neurofibromatosis type 1.

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

The role of surgical biopsy in the diagnosis of glioma in individuals with neurofibromatosis-1.

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

Optic pathway gliomas in neurofibromatosis type 1: the effect of presenting symptoms on outcome.

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

Optic pathway gliomas in neurofibromatosis-1: controversies and recommendations.

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas.

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

Randomized study of two chemotherapy regimens for treatment of low-grade glioma in young children: a report from the Children's Oncology Group

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

Outcomes of Multidisciplinary Management in Pediatric Low-Grade Gliomas

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

Gliomas presenting after age 10 in individuals with neurofibromatosis type 1 (NF1).

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

Glioblastoma multiforme in the posterior cranial fossa in a patient with neurofibromatosis type I.

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

Neoplasms Associated with Germline and Somatic NF1 Gene Mutations

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

Malignant peripheral nerve sheath tumours in neurofibromatosis 1

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

Association between benign and malignant peripheral nerve sheath tumors in NF1.

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

[18F]2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): a long-term clinical study

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

Comparative effectiveness of 18F-FDG PET/CT versus whole-body MRI for detection of malignant peripheral nerve sheath tumors in neurofibromatosis type 1.

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

(18)F-FDG PET/CT for monitoring treatment responses to the epidermal growth factor receptor inhibitor erlotinib

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

Role of resection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis type 1

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

Malignant schwannoma--clinical characteristics, survival, and response to therapy

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

Malignant peripheral nerve sheath tumours in NF1: improved survival in women and in recent years

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

Pediatric Malignant Peripheral Nerve Sheath Tumor: The Italian and German Soft Tissue Sarcoma Cooperative Group

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

First-line chemotherapy for malignant peripheral nerve sheath tumor (MPNST) versus other histological soft tissue sarcoma subtypes and as a prognostic factor for MPNST: an EORTC soft tissue and bone sarcoma group study

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

Gastrointestinal Stromal Tumors, Intramural Leiomyomas, and Leiomyosarcomas in the Duodenum: A Clinicopathologic, Immunohistochemical, and Molecular Genetic Study of 167 Cases

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

Gastrointestinal stromal tumors in patients with neurofibromatosis 1: a clinicopathologic and molecular genetic study of 45 cases

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

Molecular pathogenesis of multiple gastrointestinal stromal tumors in NF1 patients

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

Gastrointestinal and retroperitoneal manifestations of type 1 neurofibromatosis.

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO.

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

Absence of c-kit gene mutations in gastrointestinal stromal tumours from neurofibromatosis type 1 patients

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

Response to imatinib in KIT- and PDGFRA-wild type gastrointestinal stromal associated with neurofibromatosis type 1

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

Therapeutic consequences from molecular biology for gastrointestinal stromal tumor patients affected by neurofibromatosis type 1.

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

Effect of sunitinib on metastatic gastrointestinal stromal tumor in patients with neurofibromatosis type 1: a case report

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

Women with neurofibromatosis 1 are at a moderately increased risk of developing breast cancer and should be considered for early screening

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

Mortality in neurofibromatosis 1: in North West England: an assessment of actuarial survival in a region of the UK since 1989.

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

Are we ready for targeted early breast cancer detection strategies in women with NF1 aged 30-49 years?

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

Loss of the normal NF1 allele from the bone marrow of children with type 1 neurofibromatosis and malignant myeloid disorders

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

Risk of benign tumours of nervous system, and of malignant neoplasms, in people with neurofibromatosis: population-based record-linkage study

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

Neurofibromatosis and childhood leukaemia/lymphoma: a population-based UKCCSG study

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

Pheochromocytoma: evaluation, diagnosis, and treatment

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

Pheochromocytoma: diagnosis and management update

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

Treatment of malignant pheochromocytoma/paraganglioma with cyclophosphamide, vincristine, and dacarbazine: recommendation from a 22-year follow-up of 18 patients

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

131I-metaiodobenzylguanidine therapy of neuroblastoma and other neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

Periampullary and duodenal neoplasms in neurofibromatosis type 1: two cases and an updated 20-year review of the literature yielding 76 cases

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

Ampullary somatostatinomas and jejunal gastrointestinal stromal tumor in a patient with Von Recklinghausen's disease

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

Treatment of nonmetastatic rhabdomyosarcoma in childhood and adolescence: third study of the International Society of Paediatric Oncology--SIOP Malignant Mesenchymal Tumor 89.

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

Perinatal or adult Nf1 inactivation using tamoxifen-inducible PlpCre each cause neurofibroma formation

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

Plexiform and dermal neurofibromas and pigmentation are caused by Nf1 loss in desert hedgehog-expressing cells

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

Neurofibromas in NF1: Schwann cell origin and role of tumor environment

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

Inactivation of NF1 in CNS causes increased glial progenitor proliferation and optic glioma formation

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

Mouse models of tumor development in neurofibromatosis type 1

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

Mouse tumor model for neurofibromatosis type 1

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

Genetic analysis of mammalian GAP expressed in yeast.

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

The catalytic domain of the neurofibromatosis type 1 gene product stimulates ras GTPase and complements ira mutants of S. cerevisiae

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors.

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

Preclincial testing of Sorafenib and RAD001 in the Nfflox/flox;DhhCre mouse model of plexiform neurofibroma using magnetic resonance imaging

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

Preclinical cancer therapy in a mouse model of neurofibromatosis-1 optic glioma.

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

CXCR4/CXCL12 mediate autocrine cell- cycle progression in NF1-associated malignant peripheral nerve sheath tumors

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

TORC1 is essential for NF1-associated malignancies

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

Astrocyte-specific inactivation of the neurofibromatosis 1 gene (NF1) is insufficient for astrocytoma formation.

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

Neurofibromatosis-1 (Nf1) heterozygous brain microglia elaborate paracrine factors that promote Nf1-deficient astrocyte and glioma growth.

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

Increased c-Jun-NH2-kinase signaling in neurofibromatosis-1 heterozygous microglia drives microglia activation and promotes optic glioma proliferation.

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021

Optimizing biologically targeted clinical trials for neurofibromatosis.

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(14)70063-8

7 January 2021